Akanocure Pharmaceuticals Inc.

Akanocure Pharmaceuticals Inc. is a for-profit corporate entity registered in the System for Award Management (SAM.gov) since January 2015, with a registration valid through March 2025. The company appears to be a pharmaceutical research and development organization focused on developing innovative therapeutic solutions, particularly in the area of antiviral and immunomodulatory treatments. While limited publicly available information exists about the company's comprehensive background, its federal grant award history demonstrates a strong commitment to advancing scientific research through Small Business Innovation Research (SBIR) programs.

The company has received multiple federal grant awards from the National Science Foundation, primarily focusing on advanced pharmaceutical research and development. Its most recent and significant award is a $1,000,000 Cooperative Agreement for lead optimization studies of a novel, broad-spectrum antiviral and immunomodulatory agent targeting coronaviruses. Previous grants include a Phase I SBIR grant in 2021 for COVID-19 related research on an antiviral agent (AK-423), and a Phase II SBIR grant in 2020 for developing a chiral carbon catalog platform with potential industrial applications. These grants consistently demonstrate Akanocure's expertise in pharmaceutical innovation, with a particular emphasis on developing virus-agnostic therapeutic approaches that can suppress viral replication and modulate immune responses. The company's research appears to be strategically aimed at creating adaptable medical solutions that can address emerging viral threats and complex immune system challenges.